Summary

Summary Partim Bilcke: Health economics and mathematical models of infectious diseases

5 purchases

Course
Health economics and mathematical models (2108FBDBMW)

Institution
Universiteit Antwerpen (UA)

Summary of the part of the course Health economics and mathematical models of infectious diseases given by professor Bilcke. Including solutions to the exercise on the flu intervention. Includes all class notes.

[Show more]

Preview 2 out of 14 pages

View example

Uploaded on November 26, 2022
Number of pages 14
Written in 2022/2023
Type Summary

bilcke
health economics
biomedical sciences
uantwerp
health economics and mathematical models of infectious diseases
infectious and tropical diseases

Institution
Universiteit Antwerpen (UA)
Education
Biomedische Wetenschappen
Course
Health economics and mathematical models (2108FBDBMW)

Bi0med

Member since 5 year 519 documents sold

$7.21

Add to cart

Save

100% satisfaction guarantee
Immediately available after payment
Both online and in PDF
No strings attached

Health economics: prof. Bilcke
LESSON 1: ECONOMIC EVALUATION: BASIC CONCEPTS WITH FLU EXERCISE
We use SIR models, ABM and network models… to see how an infection spreads in a population &
the impact of different interventions. Interventions mostly aim to reduce infection, but can also
reduce severity of disease, such as hospitalization. This is the input for the economic model: we want
to identify the cost-effect of the intervention: intervention that gives most value for a given amount
of money. Besides disease burden, we also need other info to say something about cost-
effectiveness:

- The cost of the intervention/treatment of the disease
- Willingness to pay value
- Most widely used health outcome in health evaluation: QALYs

Within health economic evaluation we want to measure the cost-effectiveness. This can be done by
the ICER or the INMB. You need this & the willingness to pay to measure cost-effectiveness

WHAT IS ECONOMIC EVALUATION?
“COMPARATIVE ANALYSIS OF ALTERNATIVE COURSES OF ACTION IN TERMS OF BOTH THEIR COSTS AND
CONSEQUENCES .”

Consequences can be measured as QALYs, life years gained…

TYPES OF ECONOMIC EVALUATION DIFFER IN HOW HEALTH GAINS ARE VALUED
1. Cost-effectiveness analysis:
- In one-dimensional natural units
o E.g. infections prevented/hospitalisation/death prevented/life-years gained
o Heart attacks/ cancers/ strokes / deaths prevented
- Incremental cost-effectiveness ratio: ICER = ∆costs/∆effects
o E.g. $10,000 per life-year gained

2. Cost-utility analysis:

2/ - In combined measure of morbidity and mortality
o E.g. Quality-Adjusted Life Years (QALYs) gained
- Incremental cost-utility ratio: ICUR = ∆costs/∆effects
o E.g. $11,250 per QALY gained
- Incremental net monetary / health benefit
o INMB = ∆effects * K - ∆costs
o INHB = ∆effects – (∆costs/K)
 E.g. INMB = $19,000 for K = $35,000 per QALY gained
 If INMB is -20.000 euros it’s not cost-effective compared to the old one

3.
2/

, Cost-benefit analysis:
- in monetary terms ($)

DECIDING RELATIVE TO SOCIETAL WILLINGNESS TO PAY “K”
The 4 squares are called the 4 cost-effectiveness planes.

See more on this in the lectures of prof. Beutels!

Decision rules:

FLU EXERCISE
What is the cost-effectiveness of influenza vaccination in the elderly? Assume:

1. Elderly = “>65y” , ~ 2,500,000 people
2. Probability of infection = 4% = (here) clinical attack rate
3. Probability of hospitalisation if infected = 10%
4. Probability of death if infected = 3% (applies to all infections)
5. Effectiveness of vaccine = 60%
6. Uptake of the vaccine 80% (compare to no vaccination (uptake=0%))
7. Price of the vaccine per dose = $ 10
8. Administration costs per vaccine dose = $50, and
a. No fixed administration costs
b. No adverse events (i.e. no side effects of vaccination)
9. Costs per hospitalised case = $2000
10. Costs per non-hospitalised case = $100
11. Average life-expectancy > 65y = 12y
12. Costs of follow-up = $0

WHICH COST-EFFECTIVENESS OUTCOMES WILL WE USE?
- Cost per infection prevented
- Cost per death averted
- Cost per life-year gained

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller Bi0med. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $7.21. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

66184 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 15 years now

Start selling

Summary

Summary Partim Bilcke: Health economics and mathematical models of infectious diseases

Document information

Subjects

Written for

Seller

Reviews received

Content preview